Skip to content

A multicenter clinical study of roxadustat to improve outcomes in peritoneal dialysis patients

A multicenter clinical study of roxadustat to improve outcomes in peritoneal dialysis patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200065296
Enrollment
Unknown
Registered
2022-11-01
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease

Interventions

Case series:none

Sponsors

Shanghai East hospital (East Hospital Affiliated to Tongji University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 18 years old<= age <= 75 years old, stable dialysis for more than 6 months regular use of erythroietin subcutaneous injection or oral roxadust.

Exclusion criteria

Exclusion criteria: Patients with hematological diseases such as liver CIRRHOSIS, active TUBERCULOSIS, severe valvular heart DISEASE, severe underlying heart disease, AND conversion from hemodialysis to peritoneal dialysis were excluded

Design outcomes

Primary

MeasureTime frame
Cardiovascular death;

Secondary

MeasureTime frame
Blood biochemical examination;

Countries

China

Contacts

Public ContactLiu Na

Shanghai East hospital (East Hospital Affiliated to Tongji University)

naliubrown@163.com+86 18918958730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026